Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_1
2
50%
Ph phase_2
1
25%
Ph not_applicable
1
25%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 21 (25.0%)
N/A1 (25.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

NCT00445965
completednot_applicable

Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma

NCT00058370
completedphase_1

Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma

NCT00450827
completedphase_1

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

NCT00003022

Clinical Trials (4)

Showing 4 of 4 trials
NCT00445965Phase 2

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Completed
NCT00058370Not Applicable

Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma

Completed
NCT00450827Phase 1

Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma

Completed
NCT00003022Phase 1

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

Completed

All 4 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
4